Esketamine

2022 Spravato Drug Market Forecast Report to 2032 - Insights on Mechanism of Action, Dosage and Administration - ResearchAndMarkets.com

Retrieved on: 
måndag, oktober 3, 2022
Pharmaceutical, Health, Mental Health, Depression, Ethanol, Water, Research, Clinical trial, Atomic mass, Esketamine, NMDA, Methanol, Depression (mood), Treatment, SWOT, United Kingdom, Fine chemical, Pharmaceutical industry, Risk management

The "SPRAVATO Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "SPRAVATO Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive insights about SPRAVATO for Treatment Resistant Depression in seven major markets.
  • The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities.
  • Further, it also consists of future market assessments inclusive of the SPRAVATO market forecast analysis for Treatment Resistant Depression in 7MM, SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Treatment Resistant Depression.

Scientists Create Non-Psychedelic Compound with Same Anti-depressant Effect

Retrieved on: 
onsdag, september 28, 2022
Mental Health, Research, Other Natural Resources, Other Health, Alternative Medicine, Health, Other Science, Science, Natural Resources, Tao, Selective serotonin reuptake inhibitor, National, Depression, Human, THP, LSD, DARPA, Patient, UNC, 5-HT2A, R-69, Anxiety, Research, Hallucination, Psychiatry, Eugene Higgins, Mouse, Serotonin, Doctor of Philosophy, DMT, Â, UCSF, Duke, Ketamine, Michael Hooker, FDA, MD, UNC School of Medicine, University of North Carolina at Chapel Hill, Stanford University, AstraZeneca, Permeability, Tony Hawk's Pro Skater 1 + 2, Department, Mount Sinai, Brain, Zehnder Confair, Psilocybin, Esketamine, Ellman, Neurochemistry, Defense, University of California, San Francisco, Protein, Cell, N,N-Dimethyltryptamine, Substance abuse, SSRI, Department of Defense Office of Inspector General, Multimedia, Neuron, Pharmaceutical industry, Yale University, Medicine, Pharmacology, Chemistry, Nature

Some advocates and scientists believe the actual psychedelic trip hallucinations and profound emotional experiences is what leads to long-lasting therapeutic effects.

Key Points: 
  • Some advocates and scientists believe the actual psychedelic trip hallucinations and profound emotional experiences is what leads to long-lasting therapeutic effects.
  • Other scientists speculate that if the trip could be eliminated from such drugs, then only the therapeutic effects might remain.
  • We were basically running a chemistry experiment to see if we could create a compound to activate 5-HT2A.
  • It would be a game changer to create a one-dose, long-acting therapy to help people with treatment-resistant depression and other conditions.

Numinus Expands Ketamine Therapy for Mental Health in Montreal and announces new brand awareness initiatives

Retrieved on: 
torsdag, september 22, 2022
Health, Professional, List of cosmic entities in Marvel Comics, TSX, COVID-19, Ketamine, Policy, Public opinion, City, Addiction, American, Esketamine, Company, Special access program, Growth, Acquisition, Industry, Forward-looking statement, Government, Mental health, Patient, Risk, Community Access Program, Trauma, CEO, Pain, Perception, Meditation, Anxiety, Research, Marketing, Awareness, Public relations, Depression, Pharmaceutical industry, BC

Numinus continues to focus on the safe, evidence-based use of ketamine in combination with traditional therapy.

Key Points: 
  • Numinus continues to focus on the safe, evidence-based use of ketamine in combination with traditional therapy.
  • Numinus currently offers a six-week ketamine-assisted therapy program for indications including depression, addiction, and trauma and anxiety.
  • "Numinus recognizes that people in Montreal can benefit from having more treatment options, including ketamine," said Payton Nyquvest, Numinus Founder and CEO.
  • The collaboration offers an opportunity to drive cultural awareness around psychedelic-assisted therapy and mental health, while also driving increased brand awareness for Numinus.

Numinus provides update on acquisition integration and announces new client financing options

Retrieved on: 
tisdag, september 13, 2022
Health, Professional, Time, TSX, Special Accession Programme for Agriculture and Rural Development, TMS, MD, Transcranial magnetic stimulation, Legislation, Esketamine, Company, Acquisition, Growth, News, Topical steroid withdrawal, Patient, Clinical trial, Risk, Trauma, CEO, Pain, Special access program, Anxiety, Research, KAT, SVP, Depression, Mission statement, Pharmaceutical industry, List of cosmic entities in Marvel Comics, BC

During August, more than 6,200 client appointments were held across Canada and the US, representing 25% growth compared to July.

Key Points: 
  • During August, more than 6,200 client appointments were held across Canada and the US, representing 25% growth compared to July.
  • "Impressively, 15% of the client appointments held in August at our US clinics were from new clients."
  • Ketamine Therapy sessions at Numinus' US clinics (including KAT, Spravato and Ketamine medicine) grew 35% in August, compared to July, to 1,520 appointments.
  • Offered through iFinance, a third-party financing partner, Numinus' new financing option will allow Canadian clients to apply for financing with interest rates based on the applicant's credit history.

Psychedelic Drugs Global Market Report 2022: Featuring Key Players Johnson & Johnson, Pfizer, Hikma Pharmaceuticals & Others - ResearchAndMarkets.com

Retrieved on: 
fredag, augusti 5, 2022
Mental Health, Arts, Museums, Entertainment, Other Health, Alternative Medicine, Managed Care, Music, General Health, Pharmaceutical, Health, Opioid, Depression, Johnson & Johnson, Hallucinogen, Lysergic acid diethylamide, Salvia, National Alliance on Mental Illness, Growth, Brain, Behavior, Plant, Perception, Narcolepsy, Patient, Lists of diseases, National Alliance, GHB, LSD, Panic, Mental disorder, Post-traumatic stress disorder, Esketamine, Thought, Pharmacy, PTSD, Gamma-Hydroxybutyric acid, Mental, NAMI, Organization, Pharmaceutical industry, Medicine, Ketamine, Phencyclidine

The "Psychedelic Drugs Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Psychedelic Drugs Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • These drugs are a group of substances that usually alter and enhance perception, thinking processes, energy levels, and promote mental experiences.
  • Major companies operating in the psychedelic drug market are introducing nasal-spray drugs for major depressive disorders to sustain their position in the market.
  • For instance, in March 2019, Johnson & Johnson, a US-based company that manufactures psychedelic drugs and pharma medicines, launched a new depression spray named Spravato.

TMS Health and Wellness Welcomes Board-Certified Psychiatrist To Its Premier Clinical Care Team

Retrieved on: 
onsdag, juli 13, 2022
Aurora, Intensive care unit, Azusa Pacific University, Professional, Aromatherapy, TMS, Homeopathy, Health, PMHNP, Rehabilitation, Meditation, Transcranial magnetic stimulation, Harvard University, Jean-Louis Vincent, COVID, Patient, DTM&H, MSN, Brain, Diagnosis, Lists of diseases, Pediatric intensive care unit, Empathy, CA, Critical care, Medicine, Medical imaging, Esketamine, Wellness, Ketamine

COSTA MESA, Calif., July 13, 2022 /PRNewswire-PRWeb/ -- TMS Health and Wellness (TMSHW) today announced the addition of Sylvia C. Guthrie, MSN, PMHNP-BC, to the experienced therapeutic healthcare staff at its clinic in Costa Mesa, California. Guthrie brings over seven years of experience to TMSHW, including a proven ability to oversee care for critically ill patients, deliver psychiatric mental health assessments, and diagnose and treat illness. Before joining TMSHW, Guthrie spent much of her career as a charge nurse at Aurora Las Encinas Mental Health Hospital in Pasadena, CA, where she managed staff and precepted nursing students and clinical duties. She holds a board certification as a critical care registered nurse and is proud to have supported the Orange County community during the height of the COVID pandemic. Guthrie treats patients of all ages and walks of life, with a particular interest in Transcranial Magnetic Stimulation (TMS) Therapy, the specialty of TMSHW.

Key Points: 
  • Guthrie treats patients of all ages and walks of life, with a particular interest in Transcranial Magnetic Stimulation (TMS) Therapy, the specialty of TMSHW.
  • "TMS Health and Wellness is delighted to welcome Sylvia to our patient care team," says Dr. Claudia Eppele, M.D., founder and Chief Medical Officer at TMS Health and Wellness.
  • TMS Health and Wellness continues to advance treatment alternatives by offering both rTMS and Deep Transcranial Magnetic Stimulation (dTMS), utilizing the latest H-coil technology.
  • About TMS Health and Wellness: Founded by Harvard-trained doctor, Claudia Eppele M.D., TMS Health and Wellness is one of the nation's premier Transcranial Magnetic Stimulation therapy centers.

Numinus completes acquisition of Novamind and announces executive appointments

Retrieved on: 
lördag, juni 11, 2022
Mission statement, Psychotherapy, Time, Company, Lists of diseases, Trauma, Pain, Toronto Stock Exchange, Medical director, Certification, Psycho-oncology, Psychedelic therapy, University, RSU, Cancer, CSE, Canadian Securities Exchange, Depression, Legislation, Transaction, CEO, Partnership, Center, Par value, Multidisciplinary Association for Psychedelic Studies, MD, Psychiatry, MAPS, Indian stock exchange, SEDAR, Experiential learning, Anxiety, Supreme Court of British Columbia, Patient, Alternative, Acquisition, TSX, Ketamine, California Institute for Quantitative Biosciences, Research, News, FDA, Growth, Clinic, Brigham Young University, Risk, Nursing care plan, Cost-exchange ratio, Opioid use disorder, Medicine, Pharmaceutical industry, Security (finance), Esketamine, List of cosmic entities in Marvel Comics, BC

This acquisition significantly grows Numinus' client service offerings, geographic reach, and revenues.

Key Points: 
  • This acquisition significantly grows Numinus' client service offerings, geographic reach, and revenues.
  • Numinus is also pleased to announce the appointments of Dr. Reid Robison (MD) as Chief Clinical Officer and Dr. Paul Thielking (MD) as Chief Science Officer, who both join the Company from Novamind.
  • As approved by shareholders on June 8, 2022, Numinus has issued 43,474,659 common shares to the former shareholders and RSU holders of Novamind, as consideration for the acquisition representing 0.84 of one (the "Exchange Ratio") Numinus common share per each Novamind share and Novamind restricted share unit (RSU).
  • Given securities processing times, these Numinus shares should settle in Novamind investor accounts by June 16, 2022.

Kareo and PatientPop’s Integrated Platform Leveraged by Pain Management and Wellness Specialists to Scale Practice

Retrieved on: 
tisdag, maj 31, 2022
Cardiology, Data Management, Practice Management, Physical Therapy, Technology, Managed Care, Health, Mental Health, Software, Internet, Dental, Senior, EHR, Pain, Deloitte Technology Fast 500, Arthralgia, Wellness, Patient, Pain management, Health, Workflow, Silicon, Â, COVID-19, Depression, Murder Inc. Records, Industry, Time, Life, Technology, Practice management, Chronic pain, Back pain, SEO, Spine, Anesthesiology, MD, Consumer, Esketamine, Hospital, Kareo, KLAS, PLLC

Bellevue Pain and Wellness chose Kareo Clinical because its interface is tailored to the physician practitioner with a personalized workflow, and Kareo Billing because they are integrated, making it easier and faster for the practice to get paid.

Key Points: 
  • Bellevue Pain and Wellness chose Kareo Clinical because its interface is tailored to the physician practitioner with a personalized workflow, and Kareo Billing because they are integrated, making it easier and faster for the practice to get paid.
  • We are proud to partner with Bellevue Pain and Wellness to help the organization grow its practice and cultivate long-term relationships with patients.
  • About Bellevue Pain and Wellness, PLLC
    Bellevue Pain and Wellness, PLLC is a pain management, spine, and back specialist serving Bellevue and Seattle, Washington.
  • Dr. Bowers provides patient-focused treatment plans to address back pain, joint pain, and other chronic pain issues.

Braxia Scientific CEO to Speak at American Psychiatric Association Annual Meeting on Treatment Resistant Depression and Ketamine Guidelines Published in American Journal of Psychiatry

Retrieved on: 
onsdag, maj 18, 2022
Lists of diseases, Company, The American Journal of Psychiatry, Best practice, Implementation, News, American, Multimedia, American Psychiatric Association, OTC, Disorder, Rapids, Psilocybin, Review, Treatment, CDSA, Controlled Drugs and Substances Act, Depression, CSE, Esketamine, Forward-looking statement, Safety, Risk, Psychiatry, Euro-Excellence Inc v Kraft Canada Inc, Drug prohibition law, American Journal, Health Canada, Person, RWD, Removal of cannabis from Schedule I of the Controlled Substances Act, Treatment-resistant depression, Medical device, Pharmaceutical industry, Audit, Ketamine

Dr. McIntyre will participate in two discussions addressing members of the American Psychiatric Association.

Key Points: 
  • Dr. McIntyre will participate in two discussions addressing members of the American Psychiatric Association.
  • The presentation will also cover real-world data (RWD) with respect to efficacy, safety, and tolerability of ketamine treatment in adults with mood disorders.
  • For more information please visit the American Psychiatric Association Annual Meeting website.
  • Braxia Scientific is a medical research company with clinics that provide innovative ketamine treatments for persons with depression and related disorders.

Wesana Health Reports Q4 2021 Financial Results and Provides Subsequent Period Highlights

Retrieved on: 
tisdag, maj 3, 2022
Board, Imipramine, COVID-19, Traumatic brain injury, Psilocybin, Population, Drug discovery, Placement, IND, PCT, Maintenance, Cannabidiol, Clinic, Failure, TBI, Company, Biotechnology, Depression, SVS, Fungus, Patient, Trial of the century, Review, Pharmacology, Cyclothymia, Risk, Clinical trial, Hierarchy, FDA, Human, GMP, Patent, CAD, MD, Psychotherapy, Phrase, Health, Lists of diseases, MDD, Mental health, OCD, News, Research, Central nervous system, Consultant, World Intellectual Property Organization, SEDAR, Security (finance), Medical device, Pharmaceutical industry, Hospital, Risk management, Esketamine

On March 22, 2022, Wesana delivered data from an animal study, conducted by an independent global laboratory services provider in a validated model of depression.

Key Points: 
  • On March 22, 2022, Wesana delivered data from an animal study, conducted by an independent global laboratory services provider in a validated model of depression.
  • The Company believes the written response provides a path to agreements on IND-enabling studies and validates the teams effort and accomplishments over the past year.
  • On January 18, 2022, Wesana shared positive results of an animal study on a novel depression treatment protocol.
  • Medical billings1 from Wesana Clinics increased 30% in the first quarter of 2022 as compared to the fourth quarter of 2021.